3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
37
Lung Neoplasms
21
Brain Neoplasms
21
Prostatic Neoplasms
20
Pancreatic Neoplasms
20
Neoplasm Metastasis
20
Carcinoma, Hepatocellular
17
Melanoma
15
Breast Neoplasms
12
Squamous Cell Carcinoma of Head and Neck
8
Carcinoma, Renal Cell
8
Neoplasms
7
Small Cell Lung Carcinoma
6
Liver Neoplasms
6
Glioblastoma
6
Sarcoma
5
Head and Neck Neoplasms
4
Salivary Gland Neoplasms
3
Recurrence
3
Kidney Neoplasms
3
Gliosarcoma
3
Glioma
3
Colorectal Neoplasms
3
Colonic Neoplasms
3
Cholangiocarcinoma
3
Adenocarcinoma of Lung
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Sarcoma, Ewing
2
Interventions
Bevacizumab
3
Temozolomide
2
Sorafenib
2
pembrolizumab
1
Valproic Acid
1
Therapeutics
1
Sildenafil Citrate
1
Radiosurgery
1
Irinotecan
1
Equipment and Supplies
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Neurologic Manifestations
×
Radiosurgery
×
Clear all
NCT01120639
2021-08-06
Tx-Treatment
Stanford University
Phase 1/2
Completed
30 enrolled
19 charts